Christine Ordija

Christine Ordija is a highly experienced scientist specializing in molecular biology and analytical development, currently serving as Scientist II at Verve Therapeutics, where expertise includes conducting potency assays for gene editing drug products targeting atherosclerotic cardiovascular disease (ACVD). Previous roles include work at Sana Biotechnology, Inc. focusing on islet cell therapy for Type 1 Diabetes, and contract research at CRISPR Therapeutics, Inc., contributing to regenerative medicine. Christine's extensive background spans safety consulting, laboratory operations, and academic research, with a PhD from Harvard in Biological Sciences in Public Health, complemented by a Master's degree in Infectious Disease Epidemiology from Yale and a Bachelor's from Boston University.